Australialive Biomedical Forum
Biomedical Forum
Wednesday 22nd September 2010
The Australian State Government Agents General would like to extend an invitation to what promises to be one of the most exciting and insightful biomedical science events of the year!
Please join us for this important discussion bringing together researchers and financiers in the biomedical sector from Australia and the UK. The event will profile innovative research activity and commercialisation emerging from Australia, with an emphasis on collaboration with the UK; and workshop with industry financiers around how to increase effectiveness of the funding of this research in both countries.
Date Wednesday 22nd September 2010
Time 12.45pm start with informal sandwich lunch, for prompt start at 1.30pm.
5.30pm forum closure to be followed by networking reception featuring Premium Australian wines.
Venue Downer Room (1st Floor), Australia House, The Strand, London WC2B 4LA
RSVP to
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
to secure your place. Please bring photo ID to enter Australia House.
The event will be chaired by Sir William Castell, Chairman of the Wellcome Trust, and Dame Sally Davies, Director General of Research and Development and Chief Scientific Advisor for the Department of Health and NHS.
The event will feature the following eminent scientists as speakers on the researcher panel:
Nobel Laureate Professor Barry J Marshall AC (University of Western Australia)– awarded the Nobel Prize for Physiology or Medicine 2005, in conjunction with Dr Robin Warren, in recognition of their 1982 discovery that a bacterium, Helicobacter pylori, causes one of the most common and important diseases of mankind, peptic ulcer disease. His achievements have been widely recognised and he is the recipient of many awards. Read more…
Professor Nadia Rosenthal, PhD- founded the Australian Regenerative Medicine Institute at Monash University, Victoria, which serves as Headquarters for the EMBL Australia Partner Laboratory Network. She is the recipient of numerous awards and honours including the Ferrari-Soave Prize in Cell Biology. In the last decade her focus on the biology of insulin-like growth factors has led to significant advances in novel cell-based therapies for muscle ageing and heart disease. Read more...
Professor William N. Charman, PhD (Monash University)- Dean of the Faculty of Pharmacy and Pharmaceutical Sciences and Director, Monash Institute of Pharmaceutical Sciences in Melbourne, Australia. His research interests include absorption and bioavailability of poorly water soluble drugs, lymphatic drug transport, lead candidate optimisation, and the discovery and development of drugs for neglected diseases. His awards include the GlaxoWellcome International Achievement award in Pharmaceutical Sciences from the Royal Pharmaceutical Society of Great Britain, and many others. Read more...
Professor Steve Wilton, PhD (University of Western Australia) - Head of the Molecular Genetic Therapy group at the Centre for Neuromuscular and Neurological Disorders, Western Australia and President of the Australasian Gene Therapy Society. He is now evaluating the use of antisense oligomers to modify gene expression, in particular to promote exon skipping as a therapy for Duchenne muscular dystrophy, the most common and serious form of childhood muscle wasting. This exon skipping therapy can be applied to many other genetic and acquired conditions. Read more...
Professor Levon M. Khachigian, PhD (University of New South Wales)- Director of the UNSW Centre for Vascular Research. He is a vascular cell and molecular biologist who has pioneered the development of novel strategies targeting key regulatory genes in a variety of vascular disorders such as post-angioplasty restenosis, arthritis, ocular neovascularisation, tumour angiogenesis and growth. His gene-targeting “molecular assassins” will enter clinical trials in cancer patients in 2010. His innovative research has been recognised by a number of awards including the Commonwealth Health Minister's Award for Excellence in Health and Medical Research and many more. Read more...
Professor Matthew Kiernan, PhD (University of New South Wales) - Professor of Medicine UNSW and Vice President of the Australian Brain Foundation. A clinical neurologist and neuroscientist at the forefront of breakthrough research into human neurophysiology, his recent translational studies in motor neurone disease have identified abnormalities in patients before disease manifestations have appeared. The technological innovations developed as a result of this research have recently been taken up by NewSouth Innovation, the commercialisation facility of the University of NSW, for international distribution. Read more...
Investor panel:
Dr Russell Hagan - Senior Vice President, Head of New Business Strategy and Evaluation at BTG (which also has a facility in South Australia). He has 25 years experience in the pharmaceutical industry in R&D and commercial roles. BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. Read more...
Dr Ted Bianco - Director of Technology Transfer, The Wellcome Trust
Mr Michael Jones - Executive Vice President Business Development, GE Healthcare
Ms Samantha O'Connor - Director Worldwide Business Development, Pfizer Limited
Please join us.
Kerry Sanderson, Agent General for Western Australia
Sally Capp, Agent General for Victoria
Bill Muirhead, Agent General for South Australia
Andrew Craig, Agent General for Queensland
